Monopar Therapeutics Inc.
MNPR
$43.15
$1.333.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.16M | 2.88M | 3.04M | 3.12M | 3.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.16M | 7.00M | 7.49M | 8.03M | 8.83M |
| Operating Income | -16.16M | -7.00M | -7.49M | -8.03M | -8.83M |
| Income Before Tax | -15.59M | -6.47M | -7.12M | -7.61M | -8.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.59 | -6.47 | -7.12 | -7.61 | -8.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.59M | -6.47M | -7.12M | -7.61M | -8.40M |
| EBIT | -16.16M | -7.00M | -7.49M | -8.03M | -8.83M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.60 | -1.99 | -2.31 | -2.64 | -3.06 |
| Normalized Basic EPS | -2.25 | -1.25 | -1.45 | -1.65 | -1.91 |
| EPS Diluted | -3.60 | -1.99 | -2.31 | -2.64 | -3.06 |
| Normalized Diluted EPS | -2.25 | -1.25 | -1.45 | -1.65 | -1.91 |
| Average Basic Shares Outstanding | 15.12M | 13.15M | 12.45M | 11.63M | 11.06M |
| Average Diluted Shares Outstanding | 15.12M | 13.15M | 12.45M | 11.63M | 11.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |